531 related articles for article (PubMed ID: 15063573)
1. Mouse neurotoxicity test for vaccinia-based smallpox vaccines.
Li Z; Rubin SA; Taffs RE; Merchlinsky M; Ye Z; Carbone KM
Vaccine; 2004 Mar; 22(11-12):1486-93. PubMed ID: 15063573
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
3. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia virus-induced smallpox postvaccinal encephalitis in case of blood-brain barrier damage.
Garcel A; Fauquette W; Dehouck MP; Crance JM; Favier AL
Vaccine; 2012 Feb; 30(7):1397-405. PubMed ID: 22227123
[TBL] [Abstract][Full Text] [Related]
5. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.
Melamed S; Paran N; Katz L; Ben-Nathan D; Israely T; Schneider P; Levin R; Lustig S
Vaccine; 2007 Nov; 25(45):7743-53. PubMed ID: 17928110
[TBL] [Abstract][Full Text] [Related]
6. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
7. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine.
Weltzin R; Liu J; Pugachev KV; Myers GA; Coughlin B; Blum PS; Nichols R; Johnson C; Cruz J; Kennedy JS; Ennis FA; Monath TP
Nat Med; 2003 Sep; 9(9):1125-30. PubMed ID: 12925845
[TBL] [Abstract][Full Text] [Related]
8. A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.
Zhang CX; Sauder C; Malik T; Rubin SA
Biologicals; 2010 Mar; 38(2):278-83. PubMed ID: 19896867
[TBL] [Abstract][Full Text] [Related]
9. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3.
Osborne JD; Da Silva M; Frace AM; Sammons SA; Olsen-Rasmussen M; Upton C; Buller RM; Chen N; Feng Z; Roper RL; Liu J; Pougatcheva S; Chen W; Wohlhueter RM; Esposito JJ
Vaccine; 2007 Dec; 25(52):8807-32. PubMed ID: 18037545
[TBL] [Abstract][Full Text] [Related]
10. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
11. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
12. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
13. New generation smallpox vaccines: a review of preclinical and clinical data.
Artenstein AW
Rev Med Virol; 2008; 18(4):217-31. PubMed ID: 18283712
[TBL] [Abstract][Full Text] [Related]
14. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.
Handley L; Buller RM; Frey SE; Bellone C; Parker S
Expert Rev Vaccines; 2009 Jul; 8(7):841-50. PubMed ID: 19538111
[TBL] [Abstract][Full Text] [Related]
15. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.
Lewis A; Bok K; Perez O; DeFillippo J; Paolazzi C; Gomez JA
Arch Virol; 2005 Jul; 150(7):1485-91. PubMed ID: 15750861
[TBL] [Abstract][Full Text] [Related]
17. A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein.
Johnson MC; Damon IK; Karem KL
J Virol Methods; 2008 Jun; 150(1-2):14-20. PubMed ID: 18387679
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of human immunological responses to vaccinia virus.
Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.
Wittek R
Int J Infect Dis; 2006 May; 10(3):193-201. PubMed ID: 16564720
[TBL] [Abstract][Full Text] [Related]
20. Measurements of vaccinia virus dissemination using whole body imaging: approaches for predicting of lethality in challenge models and testing of vaccines and antiviral treatments.
Zaitseva M; Kapnick S; Golding H
Methods Mol Biol; 2012; 890():161-76. PubMed ID: 22688767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]